2-(4-ethoxy-phenyl)-propionitrile | 51558-05-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(4-ethoxy-phenyl)-propionitrile
• 英文别名: rac-2-(4-ethoxy-phenyl)-propionitrile；2-(4-Ethoxyphenyl)propanenitrile
• CAS: 51558-05-5
• 化学式: C₁₁H₁₃NO
• 分子量: 175.23
• InChiKey: PKWJQJIGITWZKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-ethoxy-phenyl)-propionitrile 、 1-(3-溴丙基)-3-苯氧基苯 以 N-甲基乙酰胺 为溶剂， 以88.6%的产率得到2-(4-ethoxyphenyl)-2-methyl-5-(3phenoxyphenyl) pentanonitrile
  参考文献：
  名称：

  6-pyridyl- and 6-phenyl-3-phenyl-1-hexenes and -1-hexynes, composition

  摘要：

  这项发明涉及一种由以下通用式（I）表示的新型化合物，其制备以及含有其作为活性成分的杀虫杀螨组合物： 其中R.sub.1和R.sub.2，可能相同也可能不同，是氢原子、卤素原子、较低的烷基基团、三氟甲基基团、较低的烷氧基团、较低的烯烃氧基团或卤代较低的烷氧基团或者共同为亚甲氧基团；R.sub.3是乙烯基团或乙炔基团；R.sub.4是氢原子或较低的烷基基团；R.sub.5是氢原子或氟原子；R.sub.6是氢原子、卤素原子、较低的烷基基团、较低的烷氧基团或三氟甲基基团；Z是氮原子或由--CH.dbd.表示的基团；当Z是氮原子时，Y是氧原子；当Z是--CH.dbd.的基团时，Y是氧原子、硫原子、亚甲基团或由--NH--表示的基团。

  公开号：

  US04772633A1
• 作为产物：
  描述：

  4-乙氧基苯乙腈 生成 2-(4-ethoxy-phenyl)-propionitrile
  参考文献：
  名称：

  MATSUO, NORITADA;TSUSHIMA, KAZUNORI;NISHIDA, SUMIO;YANO, TOSHIHIKO;HIRANO+

  摘要：

  DOI：

文献信息

• Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives
  申请人：Galley Guido

  公开号：US20070197621A1

  公开（公告）日：2007-08-23

  The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, R 1 , R 2 , A and n are as defined in the specification and to their pharmaceutically active salts. The invention also relates to novel compounds of formula I, pharmaceutical compositions containing them, and methods for their preparation.

  本发明涉及一种治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中R、R1、R2、A和n如规范中所定义，以及其药用活性盐。该发明还涉及化合物I的新颖化合物、含有它们的药物组合物以及它们的制备方法。
• 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
  申请人：Lim Sungtaek

  公开号：US20070244131A1

  公开（公告）日：2007-10-18

  The present invention is directed to a compound of Formula (I) wherein Cy 1 , Cy 2 , L 1 , L 2 , and R 1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

  本发明涉及一种式（I）的化合物，其中Cy1，Cy2，L1，L2和R1如本文所定义，一种制药组合物，包括一种或多种按照式（I）的化合物的药物有效量与药学可接受载体的混合物，以及一种治疗患有PGD2介导的疾病的患者的方法，包括但不限于过敏性疾病（如过敏性鼻炎，过敏性结膜炎，特应性皮炎，支气管哮喘和食物过敏），全身性肥大细胞病，伴随全身性肥大细胞激活的疾病，过敏性休克，支气管收缩，支气管炎，荨麻疹，湿疹，伴随瘙痒的疾病（如特应性皮炎和荨麻疹），疾病（如白内障，视网膜脱落，炎症，感染和睡眠障碍），这些疾病是由于伴随瘙痒的行为（如搔抓和敲打）而次生产生的，炎症，慢性阻塞性肺疾病，缺血再灌注损伤，脑血管意外，慢性类风湿性关节炎，胸膜炎，溃疡性结肠炎等，通过向该患者注射按照式（I）的化合物的药物有效量。
• 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists
  申请人：Aventis Pharmaceuticals, Inc.

  公开号：US07517889B2

  公开（公告）日：2009-04-14

  The present invention is directed to a compound of Formula (I) wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

  本发明涉及一种式(I)化合物，其中Cy1、Cy2、L1、L2和R1的定义如本文所述，一种制药组合物，包括一种或多种式(I)化合物的药物有效量与药物可接受载体混合，以及一种治疗患有PGD2介导的疾病的患者的方法，包括但不限于过敏疾病（如过敏性鼻炎、过敏性结膜炎、特应性皮炎、支气管哮喘和食物过敏）、全身肥大细胞病、伴随全身肥大细胞激活的疾病、过敏性休克、支气管收缩、支气管炎、荨麻疹、湿疹、伴随瘙痒的疾病（如特应性皮炎和荨麻疹）、由于瘙痒行为（如搔抓和打击）引起的疾病（如白内障、视网膜脱落、炎症、感染和睡眠障碍）、炎症、慢性阻塞性肺疾病、缺血再灌注损伤、脑血管意外、慢性类风湿性关节炎、胸膜炎、溃疡性结肠炎等，通过向该患者投予符合式(I)的化合物的药物有效量实施。
• Novel compound, its production and insecticidal and acaricidal composition containing it as an active ingredient
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：EP0193189A1

  公开（公告）日：1986-09-03

  This invention relates to a novel compound represented by the following general formula (I), its production, and an insecticidal and acaricidal composition containing it as an active ingredient: wherein R1 and R2, which may be the same or different, are a hydrogen atom, a halogen atom, a lower alkyl group, a trifluoromethyl group, a lower alkoxy group, a lower alkenyloxy group or a halogenated lower alkoxy group or are, taken together, a methylenedioxy group; R3 is a vinyl group or a ethynyl group; R4 is a hydrogen atom or a lower alkyl group; R5 is a hydrogen atom or a fluorine atom; R6 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxyl group or a trifluoromethyl group; Z is a nitrogen atom or a group represented by the formula -CH=; when Z is a nitrogen atom, Y is an oxygen atom; and when Z is a group of the formula -CH=, Y is an oxygen atom, a sulfur atom, a methylene group or a group represented by the formula -NH-.

  本发明涉及由以下通式(I)代表的新型化合物、其生产以及含有该化合物作为活性成分的杀虫和杀螨组合物： 其中 R1 和 R2（可以相同或不同）是氢原子、卤素原子、低级烷基、三氟甲基、低级烷氧基、低级烯氧基或卤代低级烷氧基，或合在一起是亚甲基二氧基；R3 是乙烯基或乙炔基；R4 是氢原子或低级烷基；R5 是氢原子或氟原子；R6 是氢原子、卤素原子、低级烷基、低级烷氧基或三氟甲基； Z 是氮原子或式 -CH= 所代表的基团；当 Z 是氮原子时，Y 是氧原子；当 Z 是式 -CH= 所代表的基团时，Y 是氧原子、硫原子、亚甲基或式 -NH- 所代表的基团。
• WO2008/39882
  申请人：——

  公开号：——

  公开（公告）日：——